Mutation and Protein Expression Biomarkers Correlate with Response to AKT Inhibition in a Phase I Trial of the Oral Pan AKT Inhibitor GSK2141795 (GSK795) in Patients (pts) with Platinum Resistant Ovarian Cancer - Gungor,H; Stronach,E; Curry,E; Saleem,A; Agarwal,R; Blagden,S; Babar,S; Mills,G; Morris,SR; Gabra,H (EUROPEAN JOURNAL OF CANCER, 2011)